Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Last Updated: March 23, 2023

Details for Patent: 9,333,204

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 9,333,204 protect, and when does it expire?

Patent 9,333,204 protects VIEKIRA XR and is included in one NDA.

This patent has three patent family members in three countries.

Summary for Patent: 9,333,204
Title:Solid antiviral dosage forms
Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.
Inventor(s): Miller; Jonathan M. (Lindenhurst, ID), Morris; John B. (Grayslake, IL), Sever; Nancy E. (Northbrook, IL), Schmitt; Eric A. (Libertyville, IL), Gao; Ping X. (Highland Park, IL), Shi; Yi (Libertyville, IL), Gao; Yi (Vernon Hills, IL), Liepold; Bernd (Dossenheim, DE), Moosmann; Anna (Winterbach, DE), Pauli; Mirko (Ludwigshafen, DE), Durak; Fatih (Ludwigshafen, DE), Kessler; Thomas (Schifferstadt, DE), Hoelig; Peter A. (Waechtersbach, DE), Rosenblatt; Karin (Mannheim, DE), Kostelac; Drazen (Mannheim, DE), Gokhale; Rajeev (Singapore, SG), Costello; Mark (Chicago, IL), Knable; Carl (Elmhurst, IL)
Assignee: AbbVie Inc. (North Chicago, IL)
Application Number:14/677,611
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Use;

Drugs Protected by US Patent 9,333,204

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie Inc VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 DISCN Yes No See Plans and Pricing See Plans and Pricing Y TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,333,204

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3089757 See Plans and Pricing
Taiwan 201609195 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2015103490 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.